EyeGene Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seoul Korea, Republic of (2006)

Organization Overview

First Clinical Trial
2020
NCT04210752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

EyeGene Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

eg-covid-001 (2 trials)

eg-covid-003 (1 trial)

Drugs in Phase 1 Trials (2)

Dioleoyl-3-trimethylammonium propane (1 trial)

subunit herpes zoster vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Herpes Zoster (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4